Carboplatin decreases fosphenytoin serum levels, which may lead to exacerbation of seizures.
Source: NLP:carboplatin
Carboplatin Interactions
Brand names: Carboplatin
Platinum-based Drug
Route: Intravenous
FDA Black Box Warning
Carboplatin injection should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate treatment facilities are readily available. Bone marrow suppression is dose related and may be severe, resulting in infection and/or bleeding. Anemia may be cumulative and may require transfusion support. Vomiting is another frequent drug related side effect. Anaphylactic-like reactions to carboplatin have been reported and may occur within minutes of carboplatin injection administration. Epinephrine, corticosteroids, and antihistamines have been employed to alleviate symptoms. CALVERT FORMULA FOR CARBOPLATIN DOSING Total Dose (mg) = (target AUC) × (GFR + 25) Note: With the Calvert formula, the total dose of carboplatin is calculated in mg, not mg/m 2 .
Contraindications
CONTRAINDICATIONS Carboplatin injection is contraindicated in patients with a history of severe allergic reactions to cisplatin or other platinum-containing compounds. Carboplatin injection should not be employed in patients with severe bone marrow depression or significant bleeding.
Pregnancy & Breastfeeding
Pregnancy Pregnancy Category D See WARNINGS .
7 interactions on record
Carboplatin decreases phenytoin serum levels, which may lead to exacerbation of seizures.
Source: NLP:carboplatin
Combination causes greater myelosuppression than topotecan alone with sequence-dependent interaction. Dose reduction of both agents required, particularly when coadministered on day 1 versus day 5 of topotecan dosing.
Source: NLP:topotecan
May decrease phenytoin serum levels; dose adjustment may be required.
Source: NLP:fosphenytoin sodium
Carboplatin + Phenytoin SodiumModerate
May decrease phenytoin serum levels; monitoring of phenytoin levels recommended.
Source: NLP:extended phenytoin sodium
No clinically meaningful effect on carboplatin pharmacokinetics observed when administered with bevacizumab.
Source: NLP:bevacizumab-awwb
Bexarotene had no effect on free or total carboplatin exposure. However, when combined with paclitaxel, bexarotene exposure increased 2-fold.
Source: NLP:bexarotene